基层2型糖尿病患者钠—葡萄糖共转运体2抑制剂使用专家建议  

Expert recommendations on the utilization of sodium-glucose cotransporter 2 inhibitors for patients with type 2 diabetes in primary medical institutions

作　　者：江苏省医学会糖尿病学分会基层学组 江苏省基层卫生协会内分泌专业委员会 江苏省老年医学学会老年内分泌专业委员会 江苏省预防医学会糖尿病预防与控制专业委员会 南京糖尿病并发症研究会老年分会 梁贝贝 智俊娜 唐伟 毕艳[4] The Basic Group of Diabetes Branch of Jiangsu Medical Association;Endocrinology Committee of Jiangsu Primary Health Association;Endocrinology Committee of Jiangsu Geriatric Medicine Society;Diabetes Prevention and Control Committee of Jiangsu Preventive Medicine Association;Geriatric Division of Nanjing Diabetes Communication Society;LIANG Beibei;ZHI Junna

机构地区：[1]不详 [2]南京医科大学附属老年医院内分泌科 [3]南京医科大学附属老年医院药学部 [4]南京大学医学院附属鼓楼医院内分泌科

出　　处：《中国临床研究》2024年第7期985-992,共8页Chinese Journal of Clinical Research

基　　金：江苏省重点研发计划社会发展项目(BE2023774)。

摘　　要：钠葡萄糖共转运体2抑制剂(SGLT-2i)目前越来越多地用于2型糖尿病患者的治疗,尤其是对于减轻体重和改善心血管和肾脏结局方面具有独特优势,也逐渐在基层医疗机构中广泛应用。在使用过程中,需警惕部分患者可能出现的生殖、泌尿道感染、SGLT-2i相关酮症酸中毒、低血压以及急性肾损伤风险。本建议系统通俗地介绍SGLT-2i的概念、类别、降糖机制、适应证、禁忌证、用法、超说明书方案、合并用药注意事项、不良反应及处理以及特殊患者的使用等,以帮助基层医疗机构医生规范、合理、安全使用SGLT-2i,正确掌握相关注意事项。Sodium-glucose cotransporter 2 inhibitors(SGLT-2i)are increasingly utilized in the treatment of type 2 diabetes,especially for their efficacy in weight reduction and improvement of cardiovascular and renal outcomes,and are progressively gaining widespread utilization in primary medical and healthcare institutions.During their administration,it is imperative to remain vigilant regarding the potential risks of genitourinary infections,SGLT-2i-related ketoacidosis,hypotension,and acute kidney injury in certain patients.This recommendation systematically and popularly introduces the SGLT-2i concept,classification,hypoglycemic mechanism,indications,contraindications,methods of use,super-label scheme,precautions for combined use of SGLT-2i,adverse reactions and their management,as well as the use of SGLT-2i in special patients,in order to help the doctors in primary medical and healthcare institutions to standardize,reasonably and safely use SGLT-2i and correctly grasp the relevant precautions.

关 键 词：基层医疗机构 2型糖尿病 钠葡萄糖共转运体2抑制剂 规范用药 

分 类 号：R587.1[医药卫生—内分泌]